{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:35:08Z","timestamp":1792427708424,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.kint.2025.06.005","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:22:32Z","timestamp":1767716552000},"page":"44-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)"],"prefix":"10.1016","volume":"109","author":[{"given":"Jodie L.","family":"Babitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Berns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Cheung Khedairy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarieli","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel E.","family":"Effa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele F.","family":"Eisenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fishbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena Z.","family":"Ginzburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-8994","authenticated-orcid":false,"given":"Volker H.","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Susan","family":"Hedayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3964-2046","authenticated-orcid":false,"given":"Siah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Moura-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evi V.","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5534-2516","authenticated-orcid":false,"given":"Manisha","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2508-7117","authenticated-orcid":false,"given":"Angela","family":"Yee-Moon Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee F.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3200-2492","authenticated-orcid":false,"given":"Amy","family":"Earley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie A.","family":"Akl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-3187","authenticated-orcid":false,"given":"Marcello","family":"Tonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.06.005_bib1","first-page":"279","article-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2025.06.005_bib2","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.06.005_bib3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.06.005_bib4","first-page":"5","volume":"405","year":"1968","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1016\/j.kint.2025.06.005_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ahj.2005.03.055","article-title":"Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"151","author":"Astor","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.kint.2025.06.005_bib6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0735-1097(01)01470-X","article-title":"Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction","volume":"38","author":"Al-Ahmad","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.kint.2025.06.005_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005336","article-title":"Risk factors for heart failure in patients with chronic kidney disease: the CRIC (Chronic Renal Insufficiency Cohort) Study","volume":"6","author":"He","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.kint.2025.06.005_bib8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/sj.ki.5000105","article-title":"Association of anemia with outcomes in men with moderate and severe chronic kidney disease","volume":"69","author":"Kovesdy","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.06.005_bib9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12882-022-02778-8","article-title":"Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: a retrospective observational study","volume":"23","author":"Lamerato","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0272-6386(99)70118-6","article-title":"Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin","volume":"34","author":"Levin","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.06.005_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1440-1797.2008.01065.x","article-title":"Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease","volume":"14","author":"Thorp","year":"2009","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kint.2025.06.005_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ckj\/sfz091","article-title":"Anemia and iron deficiency among chronic kidney disease stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated","volume":"13","author":"Wong","year":"2020","journal-title":"Clin Kidney J"},{"issue":"suppl 2","key":"10.1016\/j.kint.2025.06.005_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/ndt\/11.supp2.125","article-title":"Quality of life in dialysis patients: a Spanish multicentre study","volume":"11","author":"Moreno","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.06.005_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12882-020-01746-4","article-title":"Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data","volume":"21","author":"van Haalen","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib15","first-page":"565","article-title":"Economic burden of anemia in an insured population","volume":"11","author":"Nissenson","year":"2005","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.kint.2025.06.005_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12882-016-0226-6","article-title":"Anemia and risk for cognitive decline in chronic kidney disease","volume":"17","author":"Kurella Tamura","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib17","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.ajkd.2023.04.013","article-title":"Role of anemia in dementia risk among veterans with incident CKD","volume":"82","author":"Koyama","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.06.005_bib18","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/jcsm.12999","article-title":"Decreased haemoglobin levels are associated with lower muscle mass and strength in kidney transplant recipients","volume":"13","author":"Vinke","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.kint.2025.06.005_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2009-10-251496","article-title":"Iron control of erythroid development by a novel aconitase-associated regulatory pathway","volume":"116","author":"Bullock","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.kint.2025.06.005_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.20170396","article-title":"Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor","volume":"215","author":"Khalil","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.kint.2025.06.005_bib21","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/bloodadvances.2016003772","article-title":"A specialized pathway for erythroid iron delivery through lysosomal trafficking of transferrin receptor 2","volume":"1","author":"Khalil","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.kint.2025.06.005_bib22","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1172\/JCI68487","article-title":"Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response","volume":"123","author":"Richardson","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2025.06.005_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023850","article-title":"Aconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling","volume":"6","author":"Talbot","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2025.06.005_bib24","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12882-019-1244-y","article-title":"Post renal transplant anemia: severity, causes and their association with graft and patient survival","volume":"20","author":"Schechter","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.06.005_bib28","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/tri.12821","article-title":"Iron deficiency, anemia, and mortality in renal transplant recipients","volume":"29","author":"Eisenga","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.06.005_bib29","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1681\/ASN.2020101531","article-title":"Serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in nondialysis CKD patients, with or without anemia","volume":"32","author":"Guedes","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"4S","key":"10.1016\/j.kint.2025.06.005_bib30","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.06.005_bib31","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1053\/j.gastro.2020.06.046","article-title":"AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia","volume":"159","author":"Ko","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2025.06.005_bib32","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study","volume":"18","author":"Coyne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3945\/an.116.013961","article-title":"Regulation of the iron homeostatic hormone hepcidin","volume":"8","author":"Sangkhae","year":"2017","journal-title":"Adv Nutr"},{"issue":"5","key":"10.1016\/j.kint.2025.06.005_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/kisup.2015.6","article-title":"Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry","author":"Hamano","year":"2015","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.kint.2025.06.005_bib35","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.ajt.2024.03.017","article-title":"Iron deficiency, anemia, and patient-reported outcomes in kidney transplant recipients","volume":"24","author":"Kremer","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.005_bib36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13696998.2019.1588738","article-title":"Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review","volume":"22","author":"Spinowitz","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.kint.2025.06.005_bib37","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.06.005_bib38","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cardfail.2011.08.003","article-title":"Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure","volume":"17","author":"Jankowska","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.kint.2025.06.005_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.kint.2025.06.005_bib40","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kint.2025.06.005_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2025.06.005_bib42","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.06.005_bib43","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.06.005_bib44","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.06.005_bib45","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.kint.2025.06.005_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000500487","article-title":"Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial","volume":"143","author":"Akizawa","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2025.06.005_bib47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects","volume":"45","author":"Akizawa","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib48","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12882-019-1547-z","article-title":"A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis","volume":"20","author":"Bailey","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib49","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.06.005_bib50","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.06.005_bib51","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.06.005_bib52","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.06.005_bib53","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.06.005_bib54","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib55","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib56","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000464476","article-title":"Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease","volume":"45","author":"Martin","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib57","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/ndt\/gfaa060","article-title":"Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients","volume":"36","author":"Nangaku","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.06.005_bib58","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000500232","article-title":"Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study","volume":"49","author":"Parmar","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib59","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.06.005_bib60","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.06.005_bib61","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.06.005_bib62","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1681\/ASN.0000000000000321","article-title":"Daprodustat and heart failure in CKD","volume":"35","author":"Cunningham","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.06.005_bib63","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.06.005_bib64","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.06.005_bib65","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ekir.2018.02.009","article-title":"An exploratory study of daprodustat in erythropoietin-hyporesponsive subjects","volume":"3","author":"Cizman","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.06.005_bib66","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/jcpt.13696","article-title":"Addition of roxadustat to erythropoiesis-stimulating agent (ESA) effectively corrects ESA-hyporesponsive anaemia in patients on peritoneal dialysis","volume":"47","author":"Dai","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.kint.2025.06.005_bib67","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s11739-021-02738-4","article-title":"Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation","volume":"16","author":"Zhou","year":"2021","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.kint.2025.06.005_bib68","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-3-319-75402-4_22","article-title":"The role of hypoxia, hypoxia-inducible factor (HIF), and VEGF in retinal angiomatous proliferation","volume":"1074","author":"Barben","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.kint.2025.06.005_bib69","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1073\/pnas.1602978113","article-title":"HIF2\u03b1-arginase axis is essential for the development of pulmonary hypertension","volume":"113","author":"Cowburn","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2025.06.005_bib70","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1128\/MCB.01055-15","article-title":"The endothelial prolyl-4-hydroxylase domain 2\/hypoxia-inducible factor 2 axis regulates pulmonary artery pressure in mice","volume":"36","author":"Kapitsinou","year":"2016","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.kint.2025.06.005_bib71","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","article-title":"HIF-1\u03b1 promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease","volume":"94","author":"Kraus","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.06.005_bib72","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s00125-011-2081-0","article-title":"Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Muller cells","volume":"54","author":"Lin","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2025.06.005_bib73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cophys.2018.12.003","article-title":"Revisiting the role of hypoxia-inducible factors in pulmonary hypertension","volume":"7","author":"Shimoda","year":"2019","journal-title":"Curr Opin Physiol"},{"key":"10.1016\/j.kint.2025.06.005_bib74","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.tp.0000437435.19980.8f","article-title":"Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation","volume":"97","author":"Leffell","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.005_bib75","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00007890-198109000-00002","article-title":"Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients","volume":"32","author":"Opelz","year":"1981","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.005_bib76","series-title":"2010 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States","year":"2010"},{"key":"10.1016\/j.kint.2025.06.005_bib77","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1600-6143.2004.00360.x","article-title":"Predicting kidney graft failure by HLA antibodies: a prospective trial","volume":"4","author":"Terasaki","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.005_bib78","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/01.tp.0000174338.97313.5a","article-title":"Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial","volume":"80","author":"Terasaki","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.005_bib79","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1093\/ndt\/gft362","article-title":"Sensitization from transfusion in patients awaiting primary kidney transplant","volume":"28","author":"Yabu","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.06.005_bib80","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/jama.2023.12914","article-title":"Red Blood Cell Transfusion: 2023 AABB International Guidelines","volume":"330","author":"Carson","year":"2023","journal-title":"JAMA"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825004946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825004946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:33:30Z","timestamp":1778942010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825004946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0085253825004946"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.06.005","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.06.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}